• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Parkinsonism Associated with Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy.

作者信息

Schneider Sabine, Aamodt Whitley W, Pruitt Amy A, Berger Joseph R

机构信息

Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

出版信息

Mov Disord Clin Pract. 2024 Dec;11(12):1625-1628. doi: 10.1002/mdc3.14239. Epub 2024 Oct 21.

DOI:10.1002/mdc3.14239
PMID:39429213
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11647980/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c4/11647980/d3a3ca65d139/MDC3-11-1625-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c4/11647980/290dd73d0c35/MDC3-11-1625-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c4/11647980/d3a3ca65d139/MDC3-11-1625-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c4/11647980/290dd73d0c35/MDC3-11-1625-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c4/11647980/d3a3ca65d139/MDC3-11-1625-g001.jpg

相似文献

1
Parkinsonism Associated with Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy.与抗B细胞成熟抗原嵌合抗原受体T细胞疗法相关的帕金森综合征
Mov Disord Clin Pract. 2024 Dec;11(12):1625-1628. doi: 10.1002/mdc3.14239. Epub 2024 Oct 21.
2
[Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma].[可溶性B细胞成熟抗原表达与嵌合抗原受体T细胞靶向B细胞成熟抗原治疗多发性骨髓瘤患者疗效的相关性临床分析]
Zhonghua Xue Ye Xue Za Zhi. 2024 Apr 14;45(4):378-382. doi: 10.3760/cma.j.issn.0253-2727.2023.01.001.
3
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.BCMA 靶向 CAR-T 细胞治疗后出现以帕金森病为特征的神经认知和运动障碍。
Nat Med. 2021 Dec;27(12):2099-2103. doi: 10.1038/s41591-021-01564-7. Epub 2021 Dec 10.
4
Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.针对 B 细胞成熟抗原的第三代嵌合抗原受体 T 细胞治疗多发性骨髓瘤的治疗潜力。
Clin Exp Med. 2024 Apr 29;24(1):90. doi: 10.1007/s10238-024-01347-7.
5
Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.第五代嵌合抗原受体 T 细胞靶向多发性骨髓瘤中的 B 细胞成熟抗原增强抗肿瘤疗效、增殖能力和 T 细胞耗竭缓解作用。
Biomed Pharmacother. 2023 Dec;168:115691. doi: 10.1016/j.biopha.2023.115691. Epub 2023 Oct 14.
6
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原表达的血液系统恶性肿瘤。
Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
7
[Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].[抗BCMA单次输注与抗CD19嵌合抗原受体T细胞联合输注用于复发/难治性多发性骨髓瘤免疫重建的比较]
Zhonghua Xue Ye Xue Za Zhi. 2021 Sep 14;42(9):733-738. doi: 10.3760/cma.j.issn.0253-2727.2021.09.004.
8
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.γ-分泌酶抑制剂联合 BCMA 嵌合抗原受体 T 细胞免疫疗法治疗复发或难治性多发性骨髓瘤患者的 1 期、首次人体试验。
Lancet Oncol. 2023 Jul;24(7):811-822. doi: 10.1016/S1470-2045(23)00246-2.
9
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.经基因修饰表达抗 B 细胞成熟抗原嵌合抗原受体的 T 细胞可引起预后不良的复发性多发性骨髓瘤缓解。
J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.
10
Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.嵌合抗原受体 T 细胞疗法治疗骨髓瘤：我们现在处于什么位置，以及需要什么才能将嵌合抗原受体 T 细胞推进到更早的治疗线？美国移植和细胞治疗学会专家小组意见。
Transplant Cell Ther. 2024 Jan;30(1):17-37. doi: 10.1016/j.jtct.2023.10.022. Epub 2023 Oct 31.

引用本文的文献

1
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.用于cilta-cel相关运动和神经认知毒性的鞘内化疗
Blood Adv. 2025 Jul 22;9(14):3613-3616. doi: 10.1182/bloodadvances.2024015721.

本文引用的文献

1
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.嵌合抗原受体T细胞疗法治疗多发性骨髓瘤：B细胞成熟抗原（BCMA）及其他。
Vaccines (Basel). 2023 Nov 16;11(11):1721. doi: 10.3390/vaccines11111721.
2
Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.化疗诱导的 cilta-cabtagene autoleucel 相关运动和神经认知毒性逆转。
Blood. 2023 Oct 5;142(14):1248-1252. doi: 10.1182/blood.2023021429.
3
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
西达基奥仑赛，一种抗 B 细胞成熟抗原嵌合抗原受体 T 细胞疗法，用于治疗复发/难治性多发性骨髓瘤：CARTITUDE-1 研究 2 年随访结果。
J Clin Oncol. 2023 Feb 20;41(6):1265-1274. doi: 10.1200/JCO.22.00842. Epub 2022 Jun 4.
4
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.CARTITUDE 研究中接受 cilta-celgene autoleucel 治疗的多发性骨髓瘤患者的 CAR-T 神经毒性的发生率和管理。
Blood Cancer J. 2022 Feb 24;12(2):32. doi: 10.1038/s41408-022-00629-1.
5
Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma Therapy.全面的 BCMA 表达谱分析在成人正常人类大脑中表明 BCMA 靶向多发性骨髓瘤治疗的靶向神经毒性风险较低。
J Histochem Cytochem. 2022 Apr;70(4):273-287. doi: 10.1369/00221554221079579. Epub 2022 Feb 22.
6
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).成人和儿童接受嵌合抗原受体 T 细胞（CAR T）疗法的管理：欧洲血液和骨髓移植学会（EBMT）、国际干细胞治疗认证委员会和 EBMT（JACIE）联合认证委员会以及欧洲血液学协会（EHA）的 2021 年最佳实践建议。
Ann Oncol. 2022 Mar;33(3):259-275. doi: 10.1016/j.annonc.2021.12.003. Epub 2021 Dec 16.
7
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.BCMA 靶向 CAR-T 细胞治疗后出现以帕金森病为特征的神经认知和运动障碍。
Nat Med. 2021 Dec;27(12):2099-2103. doi: 10.1038/s41591-021-01564-7. Epub 2021 Dec 10.
8
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.细胞因子释放综合征及癌症免疫治疗相关神经毒性
Nat Rev Immunol. 2022 Feb;22(2):85-96. doi: 10.1038/s41577-021-00547-6. Epub 2021 May 17.
9
Revisiting amantadine as a treatment for drug-induced movement disorders.重新审视金刚烷胺作为药物性运动障碍的一种治疗方法。
Ann Clin Psychiatry. 2020 Aug;32(3):198-208.